COMPOSITIONS COMPRISING BACTERIAL STRAINS
The invention provides compositions comprising a viable bacterial strain of the genus Pediococcus , for use in treating or preventing inflammatory or autoimmune disease.
1 .- 15 . (canceled)
16 . A method of treating an inflammatory or an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a bacterial strain of the genus Pediococcus and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the bacterial strain comprises a 16s rRNA gene sequence with at least 95% sequence identity to SEQ ID NO: 1.
17 . The method of claim 16 , wherein the inflammatory or the autoimmune disease comprises graft-versus-host disease (GVHD), an inflammatory bowel disease (IBD), asthma, arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, or an allograft rejection.
18 . The method of claim 17 , wherein the IBD comprises Crohn's disease or ulcerative colitis.
19 . The method of claim 17 , wherein the asthma comprises allergic asthma or neutrophilic asthma.
20 . The method of claim 17 , wherein the arthritis comprises rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis.
21 . The method of claim 16 , wherein the bacterial strain is lyophilized.
22 . The method of claim 16 , wherein the pharmaceutical composition is formulated for oral, rectal, intranasal, buccal or sublingual administration.
23 . The method of claim 16 , wherein the bacterial strain is viable.
24 . The method of claim 16 , wherein the bacterial strain colonizes an intestine of the subject when administered to the subject.
25 . The method of claim 16 , wherein the therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU) of the bacterial strain per gram, with respect to total weight of the pharmaceutical composition.
26 . The method of claim 16 , wherein the bacterial strain comprises a 16s rRNA gene sequence with at least 98% sequence identity to SEQ ID NO: 1.
27 . The method of claim 16 , wherein the bacterial strain comprises a 16s rRNA gene sequence of SEQ ID NO: 1.
28 . The method of claim 16 , wherein the bacterial strain is of the species Pediococcus acidilactici.
29 . The method of claim 16 , wherein the bacterial strain is the strain deposited under accession number NCIMB 43172, a derivative, or a biotype thereof.
30 . The method of claim 16 , wherein the pharmaceutical composition comprises only de minimis or biologically irrelevant amounts of other bacterial strains or species.
31 . A method of maintaining gut barrier or preventing gut permeability in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a bacterial strain of the genus Pediococcus and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the bacterial strain comprises a 16s rRNA gene sequence with at least 95% sequence identity to SEQ ID NO: 1.
32 . The method of claim 31 , wherein therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU) of the bacterial strain per gram, with respect to total weight of the pharmaceutical composition.
33 . The method of claim 31 , wherein the bacterial strain comprises a 16s rRNA gene sequence with at least 98% sequence identity to SEQ ID NO: 1.
34 . The method of claim 31 , wherein the bacterial strain is of the species Pediococcus acidilactici.
35 . The method of claim 31 , wherein the bacterial strain is the strain deposited under accession number NCIMB 43172, a derivative, or a biotype thereof.